Norepinephrine-bitartrate-monohydrate-DataSheet-生命科學(xué)試劑-MedChemExpress

Hotline:400-820-3792Inhibitors?Agonists?ScreeningLibrarieswww.MedChemENorepinephrinebitartratemonohydrateCat.No.:HY-13715BCASNo.:108341-18-0分?式:C??H??NO??分?量:337.28作?靶點(diǎn):AdrenergicReceptor;Autophagy作?通路:GPCR/GProtein;NeuronalSignaling;Autophagy儲(chǔ)存?式:4°C,protectfromlight,storedundernitrogen*Insolvent:-80°C,6months;-20°C,1month(protectfromlight,storedundernitrogen)溶解性數(shù)據(jù)體外實(shí)驗(yàn)H2O:50mg/mL(148.24mM;Needultrasonic)掃描?維碼，DMSO:≥30mg/mL(88.95mM)運(yùn)?溶解?案計(jì)算器*"≥"meanssoluble,butsaturationunknown.獲得適合您實(shí)驗(yàn)體系的溶解?案MassSolvent1mg5mg10mgConcentration制備儲(chǔ)備液1mM2.9649mL14.8245mL29.6490mL5mM0.5930mL2.9649mL5.9298mL10mM0.2965mL1.4824mL2.9649mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度，選擇合適的溶劑配制儲(chǔ)備液，并請(qǐng)注意儲(chǔ)備液的保存?式和期限。體內(nèi)實(shí)驗(yàn)請(qǐng)根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥?式選擇適當(dāng)?shù)娜芙?案。以下溶解?案都請(qǐng)先按照InVitro?式配制澄的儲(chǔ)備液，再依次添加助溶劑：為保證實(shí)驗(yàn)結(jié)果的可靠性，澄的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；體內(nèi)實(shí)驗(yàn)的?作液，建議您現(xiàn)?現(xiàn)配，當(dāng)天使?；以下溶劑前顯?的百分?指該溶劑在您配制終溶液中的體積占?；如在配制過(guò)程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過(guò)加熱和/或超聲的?式助溶1.請(qǐng)依序添加每種溶劑：PBSSolubility:150mg/mL(444.73mM);Clearsolution;NeedultrasonicBIOLOGICALACTIVITY1/3www.MedChemEwww.MedChemE?物活性Norepinephrinebitartratemonohydrate(Levarterenolbitartratemonohydrate;L-Noradrenalinebitartratemonohydrate)β1-選擇性的腎上腺素能受體激動(dòng)劑，EC50為5.37μM。IC50&TargetEC50:5.37μM(β1-selectiveadrenergicreceptor)[1]體外研究Norepinephrinebitartratemonohydrate(Levarterenolbitartratemonohydrate;L-Noradrenalinebitartratemonohydrate)isgenerallyconsideredtobeaβ1-subtypeselectiveadrenergicagonist.Norepinephrine(NE)alsohasdirectactivityattheβ2-adrenoceptorinhigherconcentrations[1].Adipocytesfromtheinguinalfatpad(iWA)ortheinterscapularfatpad(BA)areisolatedfromneonatalwild-typeC57BL/6Jmiceandcultured.ToexaminetheeffectofactivatingAT2uponβ-adrenergicsignaling,cAMPproductionisfirstassessedinresponsetoNorepinephrine(NE,10μM)withorwithoutCGP(10nM)co-treatment.Norepinephrine(NE)increasescAMPasexpectediniWA,andCGPdoesnotalterthiseffect.Norepinephrine(NE)isalsoknowntoinducelipolysis,andliberatedfattyacidsarerequiredtofunctionallyactivateUCP1proteinandtostimulateheatproduction.CREBphosphorylationatSer133isincreasedafterNorepinephrine(NE)treatmentandsignificantlyattenuatedwithCGPco-treatmentinmouseiWA[2].PROTOCOLCellAssay[2]Subcutaneouspreadipocytesderivedfroma38-yearoldnon-diabeticfemaledonorareimmortalizedwithTERTandHPVE6/E7.Forthecurrentstudies,astablediploidclone(referredtoascloneB)withconsistentdifferentiationcapacityisisolatedbyringcloning.CellsaregrowninpreadipocytePGM2media.Oncecellsareconfluent,differentiationisinducedbyincubationindifferentiationmediaconsistingofdexamethasone,IBMX,indomethacin,andadditionalinsulin.Cellsaredifferentiatedfor10days.Priortotreatment,mediaisreplacedwithPGM2mediaforonedayandthenswitchedtoserum-freemediaovernightfortreatments.Adipocytesaretreatedfor6hourswithvehicle,Norepinephrine(NE,10μM),CGP(10nM),orNorepinephrine(NE)andCGP[2].MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly.戶(hù)使?本產(chǎn)品發(fā)表的科研?獻(xiàn)?CardiovascRes.2018Feb1;114(2):300-311.?CellRep.2019Dec3;29(10):2936-2943.e4.?BrJPharmacol.2020Aug;177(15):3389-3402.?CellDeathDis.2020Aug18;11(8):644.?FASEBJ.2020Nov;34(11):14892-14904.Seemorecustomervalidationsonwww.MedChemEREFERENCES[1].MacGregorDA,etal.Relativeefficacyandpotencyofbeta-adrenoceptoragonistsforgeneratingcAMPinhumanlymphocytes.Chest.1996Jan;109(1):194-200.[2].LittlejohnNK,etal.SuppressionofRestingMetabolismbytheAngiotensinAT2Receptor.CellRep.2016Aug9;16(6):1548-60.2/3www.MedChemEwww.MedChemEMcePdfHeight關(guān)注MCE中國(guó)公眾號(hào)，

獲取前沿資訊、最新活動(dòng)和

實(shí)?科研?具M(jìn)edChemExpress(MCE)只為有資質(zhì)的科研機(jī)構(gòu)、醫(yī)藥企業(yè)基于